← Back to Search

Volunteer control for Dentatorubral-Pallidoluysian Atrophy (DRPLA NHBS Trial)

N/A
Recruiting
Led By Paola Giunti
Research Sponsored by University College, London
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

DRPLA NHBS Trial Summary

DRPLA Natural History and Biomarkers Study (DRPLA NHBS) is a prospective observational study that will lay the foundation for clinical trials in DRPLA. The aims of this project are: To characterize the natural history of DRPLA in both juvenile- and adult-onset patients and study different modalities of biomarkers in this condition. To identify genetic factors and biomarkers that could predict disease progression. To provide a platform to support the design and conduct of clinical trials. This study has three arms: Adult Participants: this arm of the study will require participants to be 16 years old or over to participate. Pediatric Participants: this arm of the study will require participants to be under 16 years old to participate. Remote Participants: patients that cannot or do not wish to travel to one of the study sites can participate in this arm of the study, irrespective of their age. Participants will have an annual visit for three years (baseline visit and two follow-up visits, three visits in total). Subjects who complete the whole protocol will be assessed on two consecutive days to reduce patient burden. This project will allow for a better understanding of DRPLA and its course, and therefore allow for future clinical trials on this condition to be more precisely and effectively conducted.

Eligible Conditions
  • Dentatorubral-Pallidoluysian Atrophy

DRPLA NHBS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Brain atrophy
Neurofilament plasma concentration (NfL)
Scale for the assessment and rating of ataxia (SARA)
Secondary outcome measures
Clinical Assessment of Dysphagia in Neurodegeneration (CADN)
Glial fibrillary acidic protein (GFAP) concentration
Inventory of non-ataxia signs (INAS)
+4 more

DRPLA NHBS Trial Design

2Treatment groups
Experimental Treatment
Group I: Volunteer controlExperimental Treatment1 Intervention
Subjects without neurological conditions (other than primary headache disorders), without a family history of DRPLA or a previous negative genetic test for pathological expansions in the ATN1 gene.
Group II: DRPLA-mutation carrierExperimental Treatment1 Intervention
Subjects with a positive genetic test for a pathological expansion in the ATN1 gene.

Find a Location

Who is running the clinical trial?

NYU Grossman School of MedicineUNKNOWN
1 Previous Clinical Trials
992 Total Patients Enrolled
University of North Carolina, Chapel HillOTHER
1,504 Previous Clinical Trials
4,187,437 Total Patients Enrolled
University College, LondonLead Sponsor
833 Previous Clinical Trials
38,910,164 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~110 spots leftby Apr 2026